ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1314

Systems Analyses of Fabry Renal Transcriptome and Its Response to Enzyme Replacement Therapy (ERT) Identifies a Cross-Validated and Drugable ERT-Resistant Module

Session Information

Category: Genetic Diseases of the Kidneys

  • 1002 Genetic Diseases of the Kidneys: Non-Cystic

Authors

  • Eikrem, Oystein, Department of Medicine, Haukeland University Hospital, Bergen, Norway
  • Delaleu, Nicolas, Department of Clinical Medicine, University of Bergen, Bergen, Norway
  • Strauss, Philipp, Department of Clinical Medicine, University of Bergen, Bergen, Norway
  • Sekulic, Miroslav, Columbia University Department of Pathology and Cell Biology, New York, New York, United States
  • Tøndel, Camilla, Department of Pediatrics, Haukeland University Hospital, Bergen, Norway
  • Skrunes, Rannveig, Department of Medicine, Haukeland University Hospital, Bergen, Norway
  • Leh, Sabine, Department of Pathology, Haukeland University Hospital, Bergen, Norway
  • Svarstad, Einar, Department of Medicine, Haukeland University Hospital, Bergen, Norway
  • Rusu, Elena-Emanuela, Fundeni Clinical Institute, Bucharest, Romania
  • Gaspert, Ariana, Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland
  • Nowak, Albina, Department of Endocrinology and Clinical Nutrition, University Hospital, Zurich and University of Zurich, Zurich, Switzerland
  • Rinaldi, Andrea, Institute of Oncology Research, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
  • Marti, Hans-Peter, Department of Clinical Medicine, University of Bergen, Bergen, Norway
Background

Fabry nephropathy (FN) is a rare disorder caused by mutations in the alpha-galactosidase A gene that can, to a certain degree, be managed with enzyme replacement therapy (ERT). Via understanding the molecular basis of FN and ERT’s long-term impact, we aim at providing a framework allowing selection of biomarkers and drug-targets.

Methods

Obtained from controls and two independent FN-cohorts, mRNA-isolates from archival kidney biopsies taken prior and up to 10 years of ERT, were subjected to RNAseq. Combining pathway-centered analyses with network-science allowed computation of transcriptional landscapes from glomeruli, proximal tubuli, distal tubuli and arteries and integration with existing proteome, interactome and drug::target data.

Results

Comparing transcriptional landscapes per cohort revealed high inter-cohort heterogeneity. Especially, with timely treatment initiation, FN seemed well controlled via ERT. Pathways consistently altered in both FN-cohorts pre-ERT vs. N_CTRLs were limited to glomeruli and arteries and commonly pertained to the same biological themes. While keratinization-related processes in glomeruli were sensitive to ERT, a majority of alterations, such as transporter activity and responses to stimuli, remained dysregulated or remerged despite of ERT. Inferring an ERT-resistant genetic module on this basis identified targets suitable for drug repurposing.

Conclusion

Kidney compartments’ transcriptional landscapes comprehensively reflected differences in FN-cohort characteristics. With the exception of few key aspects, in particular concerning arteries, early ERT in classical Fabry patients could lastingly revert FN kidney-compartments’ molecular state to closely match N_CTRLs. Thus, we identified and cross-validated ERT-resistant modules that, when leveraged with external data, allowed estimating their suitability as biomarkers and potential targets for adjunct treatment.

Funding

  • Commercial Support